Latest Whitepapers

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

The need for molecular diagnostic assays is growing at an unprecedented rate and the discovery of new biomarkers and improved accessibility to standard catalog reagents has allowed the creation of molecular tests faster than ever before.

Real-time PCR, also known as quantitative PCR (qPCR), is the gold-standard for sensitive, specific detection and quantification of nucleic acid targets and qPCR methods have become core technologies for delivering high-quality results in a range of applications throughout biologics development and biomanufacturing.

Download this whitepaper to discover how the manufacturing process was successfully scaled using operational support, a customized solution as well as a highly collaborative and strategic engagement.

Download this whitepaper to discover assay development tools that can help you to image various dyes with different excitation and emission wavelengths, achieve a high degree of photostability as well as detect the presence of proteins including SARS-CoV-2's spike protein.

Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD), a liver condition that is characterized by liver steatosis accompanied by liver cell injury and inflammation.

Download this whitepaper to uncover predicting disease onset via clinical biomarkers as well as other potential applications in diabetes research.

Supply chain security and transparency is a key part of the risk mitigation strategy of companies manufacturing clinical diagnostic assays. Prior to the COVID-19 crisis, complex global supply chains carefully balanced capacity with demand while cost-cutting initiatives pushed towards lower cost raw material providers located in different geographies.

The choice of whether to outsource production of an in vitro diagnostic (IVD) or invest and develop inhouse capabilities is a foundational business decision. Capacity, capabilities and resources must all be assessed to determine the best course of action.

Biobanks and biorepositories play a crucial role in medical research by offering robust, readily available and even rare biospecimen samples for clinical, biomedical and research studies.